A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
Clinical trial NCT04640623 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04640623
- Sponsor
- Janssen Research & Development, LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-12-18
- Primary completion
- 2025-07-03
- Enrollment
- 220
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.